Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?

The investigators' preliminary data indicate that besides " free " infectious viral particles, HIV-1 infected cluster of differentiation 4 (CD4+) lymphocytes also produce extracellular viral assemblies wrapped in an extracellular matrix cocoon and tightly bound to the surface of the cell. Importantly, these structures are infectious, transferred to target cells upon intercellular contacts and they are key role in HIV-1 spread between T lymphocytes. HIV-1 viral biofilm could be important not only for direct transmission of the virions but also for " trans-infection ", a process our objectives are:

• to better characterize the molecular composition and the architecture of this biofilm (using proteomics, glycomic superresolution cell imaging approaches) with regard to its properties (infectivity, adhesiveness, protection of virions) and to determine whether cells from infected patients produce such structures.
• to delineate the viral factors regulating the formation of these new infectious structures (with a particular attention on Tat, Vpu and Nef HIV-1 encoded using mutant viruses or expression vectors).
• to investigate the lymphocyte pathways regulating the viral biofilms formation and composition in extracellular matrix (ECM) proteins (using quantitative polymerase chain reaction (qPCR) and siRNA).
• to determine whether those viral biofilms are involved in HIV-1 transmission by transinfection
• to study the contribution of those infectious structures and the dynamics of their transmission in lymph nodes.

This project may contribute to decipher the role of viral biofilms in HIV-1 transmission. Ultimately, we intend to determine how the interference of retroviral infections with T cell activation pathways modulates the pattern of ECM production by T cells, tuning viral biofilm composition and regulating viral dissemination.

Inclusion criteria

• Age ≥ 18 years
• able to give written consent
• HIV positive serology HIV1
• Viral load > 10 000 copies/ml
• CD4 T cells > 100 cells/mm3
• or Treated by antiretroviral therapy (ARV) for less than 6 months
• Covered by French Social Security

Exclusion criteria

• Involved in a clinical trial
• Pregnancy (inclusion can be postponed)
• No covered by French Social Security